Latest News

Alzheimer's Disease Research

The U.S. Food and Drug Administration today granted full approved of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain.

Jul 6, 2023
National Glaucoma Research

Initial study results of an innovative glaucoma therapy involving eye implants have yielded positive results, and a Phase 2 clinical trial of this exciting potential treatment has begun.

Jun 29, 2023
BrightFocus Foundation

BrightFocus Foundation hosted its 50th Anniversary Celebration and Awards on June 14 at the Smithsonian’s National Museum of the American Indian in Washington, D.C.

Jun 12, 2023
BrightFocus Foundation

On Wednesday, June 14, BrightFocus hosted a bipartisan congressional briefing to highlight the importance of funding and diversity in research to improve health equity and cure brain and vision diseases.

Jun 8, 2023
Alzheimer's Disease Research

In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.

Jun 2, 2023
Macular Degeneration Research

Factors that stress the body, such as obesity, can make people more likely to develop macular degeneration when they’re older, even if they’ve returned to a normal weight, new research shows.

May 31, 2023
Alzheimer's Disease Research

The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.

May 17, 2023
Press Releases

In celebration of its 50th anniversary, BrightFocus Foundation announces the launch of a yearlong campaign and microsite celebrating the international nonprofit’s strides in the fight against Alzheimer’s disease, macular degeneration, and glaucoma and toward greater awareness of the importance of funding brain and vision research and education.  

May 15, 2023
Alzheimer's Disease Research

BrightFocus honors the life of Donald L. Price, MD.

May 11, 2023
Alzheimer's Disease Research

A new BrightFocus-funded study suggests that an FDA-approved sleeping pill may slow or stop the progression of Alzheimer’s disease, promising findings that are sparking further investigation. 

May 3, 2023